AstraZeneca halts eVOLVE-Lung02 trial of volrustomig combo (AZN:NYSE)
· seekingalpha.com
AstraZeneca halts eVOLVE-Lung02 Phase III volrustomig chemo trial in metastatic NSCLC after IDMC says endpoints unlikely met; learn impacts & next steps.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...